VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY
To investigate the impact and underlying mechanisms of vitamin D-deficiency (VDD) on the outcome of elderly (61 to 80 years) patients with diffuse large B-cell lymphoma (DLBCL), we measured 413 pretreatment 25-OH-vitamin D serum levels from 2 trials (RICOVER-60 and RICOVER-noRTh) by a commercially a...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2014-04, Vol.34 (4), p.2049-2049 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2049 |
|---|---|
| container_issue | 4 |
| container_start_page | 2049 |
| container_title | Anticancer research |
| container_volume | 34 |
| creator | Bittenbring, Jorg Thomas Neumann, Frank Altmann, Bettina Achenbach, Marina Ziepert, Marita Reichrath, Jorg Held, Gerhard Pfreundschuh, Michael |
| description | To investigate the impact and underlying mechanisms of vitamin D-deficiency (VDD) on the outcome of elderly (61 to 80 years) patients with diffuse large B-cell lymphoma (DLBCL), we measured 413 pretreatment 25-OH-vitamin D serum levels from 2 trials (RICOVER-60 and RICOVER-noRTh) by a commercially available chemoluminescent immunoassay (DiaSorin, LIASON). The 359 RICOVER-60 patients with VDD (defined as serum levels < or =8 ng/ml, determined by an exploratory analysis) and treated with rituximab had a 3-year event-free survival of 59% compared to 79% in patients with vitamin D levels >8 ng/ml; 3-year overall survival was 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for IPI risk factors with a hazard ratio (HR) of 2.1 (p=0.008) for event-free and 1.9 (p=0.040) for overall survival. These results were confirmed in an independent validation set of 63 patients from the RICOVER-noRTh study. An explanatory mechanism may be impaired Rituximab-mediated cellular cytotoxicity (RMCC) in VDD individuals. RMCC was determined by LDH release assay of CD20+ Daudi cells attacked by NK-cells. In otherwise healthy volunteers with VDD (8.4+ or -3.0 ng/ml) substituted to normal values (40.6+ or -13.6 ng/ml) the RMCC increased significantly (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1551622974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1551622974</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_15516229743</originalsourceid><addsrcrecordid>eNqVy00LgjAcgPERBdnLd9ixy2Bqc3lcc9IfnIbN0JNIGBSW1fL716Ev0Om5_J4RclweuoQzn46RQz1GCaeUTdHM2iulQRBufAepIxihIcURjlQMElQqKwx6LyA_4BxMUYIWW6JVBMKoCEuVJEUiciwrk5ms_C6mWqDJuelsu_x1jlaxMnJHHq_-ObT2Xd8u9tR2XXNv-8HWLmNu4HkhX_t_0A98oDmr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1551622974</pqid></control><display><type>article</type><title>VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Bittenbring, Jorg Thomas ; Neumann, Frank ; Altmann, Bettina ; Achenbach, Marina ; Ziepert, Marita ; Reichrath, Jorg ; Held, Gerhard ; Pfreundschuh, Michael</creator><creatorcontrib>Bittenbring, Jorg Thomas ; Neumann, Frank ; Altmann, Bettina ; Achenbach, Marina ; Ziepert, Marita ; Reichrath, Jorg ; Held, Gerhard ; Pfreundschuh, Michael</creatorcontrib><description>To investigate the impact and underlying mechanisms of vitamin D-deficiency (VDD) on the outcome of elderly (61 to 80 years) patients with diffuse large B-cell lymphoma (DLBCL), we measured 413 pretreatment 25-OH-vitamin D serum levels from 2 trials (RICOVER-60 and RICOVER-noRTh) by a commercially available chemoluminescent immunoassay (DiaSorin, LIASON). The 359 RICOVER-60 patients with VDD (defined as serum levels < or =8 ng/ml, determined by an exploratory analysis) and treated with rituximab had a 3-year event-free survival of 59% compared to 79% in patients with vitamin D levels >8 ng/ml; 3-year overall survival was 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for IPI risk factors with a hazard ratio (HR) of 2.1 (p=0.008) for event-free and 1.9 (p=0.040) for overall survival. These results were confirmed in an independent validation set of 63 patients from the RICOVER-noRTh study. An explanatory mechanism may be impaired Rituximab-mediated cellular cytotoxicity (RMCC) in VDD individuals. RMCC was determined by LDH release assay of CD20+ Daudi cells attacked by NK-cells. In otherwise healthy volunteers with VDD (8.4+ or -3.0 ng/ml) substituted to normal values (40.6+ or -13.6 ng/ml) the RMCC increased significantly (p<0.05).</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><language>eng</language><ispartof>Anticancer research, 2014-04, Vol.34 (4), p.2049-2049</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Bittenbring, Jorg Thomas</creatorcontrib><creatorcontrib>Neumann, Frank</creatorcontrib><creatorcontrib>Altmann, Bettina</creatorcontrib><creatorcontrib>Achenbach, Marina</creatorcontrib><creatorcontrib>Ziepert, Marita</creatorcontrib><creatorcontrib>Reichrath, Jorg</creatorcontrib><creatorcontrib>Held, Gerhard</creatorcontrib><creatorcontrib>Pfreundschuh, Michael</creatorcontrib><title>VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY</title><title>Anticancer research</title><description>To investigate the impact and underlying mechanisms of vitamin D-deficiency (VDD) on the outcome of elderly (61 to 80 years) patients with diffuse large B-cell lymphoma (DLBCL), we measured 413 pretreatment 25-OH-vitamin D serum levels from 2 trials (RICOVER-60 and RICOVER-noRTh) by a commercially available chemoluminescent immunoassay (DiaSorin, LIASON). The 359 RICOVER-60 patients with VDD (defined as serum levels < or =8 ng/ml, determined by an exploratory analysis) and treated with rituximab had a 3-year event-free survival of 59% compared to 79% in patients with vitamin D levels >8 ng/ml; 3-year overall survival was 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for IPI risk factors with a hazard ratio (HR) of 2.1 (p=0.008) for event-free and 1.9 (p=0.040) for overall survival. These results were confirmed in an independent validation set of 63 patients from the RICOVER-noRTh study. An explanatory mechanism may be impaired Rituximab-mediated cellular cytotoxicity (RMCC) in VDD individuals. RMCC was determined by LDH release assay of CD20+ Daudi cells attacked by NK-cells. In otherwise healthy volunteers with VDD (8.4+ or -3.0 ng/ml) substituted to normal values (40.6+ or -13.6 ng/ml) the RMCC increased significantly (p<0.05).</description><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqVy00LgjAcgPERBdnLd9ixy2Bqc3lcc9IfnIbN0JNIGBSW1fL716Ev0Om5_J4RclweuoQzn46RQz1GCaeUTdHM2iulQRBufAepIxihIcURjlQMElQqKwx6LyA_4BxMUYIWW6JVBMKoCEuVJEUiciwrk5ms_C6mWqDJuelsu_x1jlaxMnJHHq_-ObT2Xd8u9tR2XXNv-8HWLmNu4HkhX_t_0A98oDmr</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Bittenbring, Jorg Thomas</creator><creator>Neumann, Frank</creator><creator>Altmann, Bettina</creator><creator>Achenbach, Marina</creator><creator>Ziepert, Marita</creator><creator>Reichrath, Jorg</creator><creator>Held, Gerhard</creator><creator>Pfreundschuh, Michael</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20140401</creationdate><title>VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY</title><author>Bittenbring, Jorg Thomas ; Neumann, Frank ; Altmann, Bettina ; Achenbach, Marina ; Ziepert, Marita ; Reichrath, Jorg ; Held, Gerhard ; Pfreundschuh, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_15516229743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bittenbring, Jorg Thomas</creatorcontrib><creatorcontrib>Neumann, Frank</creatorcontrib><creatorcontrib>Altmann, Bettina</creatorcontrib><creatorcontrib>Achenbach, Marina</creatorcontrib><creatorcontrib>Ziepert, Marita</creatorcontrib><creatorcontrib>Reichrath, Jorg</creatorcontrib><creatorcontrib>Held, Gerhard</creatorcontrib><creatorcontrib>Pfreundschuh, Michael</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bittenbring, Jorg Thomas</au><au>Neumann, Frank</au><au>Altmann, Bettina</au><au>Achenbach, Marina</au><au>Ziepert, Marita</au><au>Reichrath, Jorg</au><au>Held, Gerhard</au><au>Pfreundschuh, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY</atitle><jtitle>Anticancer research</jtitle><date>2014-04-01</date><risdate>2014</risdate><volume>34</volume><issue>4</issue><spage>2049</spage><epage>2049</epage><pages>2049-2049</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>To investigate the impact and underlying mechanisms of vitamin D-deficiency (VDD) on the outcome of elderly (61 to 80 years) patients with diffuse large B-cell lymphoma (DLBCL), we measured 413 pretreatment 25-OH-vitamin D serum levels from 2 trials (RICOVER-60 and RICOVER-noRTh) by a commercially available chemoluminescent immunoassay (DiaSorin, LIASON). The 359 RICOVER-60 patients with VDD (defined as serum levels < or =8 ng/ml, determined by an exploratory analysis) and treated with rituximab had a 3-year event-free survival of 59% compared to 79% in patients with vitamin D levels >8 ng/ml; 3-year overall survival was 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for IPI risk factors with a hazard ratio (HR) of 2.1 (p=0.008) for event-free and 1.9 (p=0.040) for overall survival. These results were confirmed in an independent validation set of 63 patients from the RICOVER-noRTh study. An explanatory mechanism may be impaired Rituximab-mediated cellular cytotoxicity (RMCC) in VDD individuals. RMCC was determined by LDH release assay of CD20+ Daudi cells attacked by NK-cells. In otherwise healthy volunteers with VDD (8.4+ or -3.0 ng/ml) substituted to normal values (40.6+ or -13.6 ng/ml) the RMCC increased significantly (p<0.05).</abstract></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2014-04, Vol.34 (4), p.2049-2049 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1551622974 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| title | VITAMIN D DEFICIENCY IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VITAMIN%20D%20DEFICIENCY%20IMPAIRS%20RITUXIMAB-MEDIATED%20CELLULAR%20CYTOTOXICITY&rft.jtitle=Anticancer%20research&rft.au=Bittenbring,%20Jorg%20Thomas&rft.date=2014-04-01&rft.volume=34&rft.issue=4&rft.spage=2049&rft.epage=2049&rft.pages=2049-2049&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest%3E1551622974%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1551622974&rft_id=info:pmid/&rfr_iscdi=true |